KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Interest Expenses: 2011-2024

Historic Interest Expenses for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $59.3 million.

  • Esperion Therapeutics' Interest Expenses rose 46.21% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year increase of 35.42%. This contributed to the annual value of $59.3 million for FY2024, which is 0.47% up from last year.
  • Esperion Therapeutics' Interest Expenses amounted to $59.3 million in FY2024, which was up 0.47% from $59.0 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Interest Expenses registered a high of $59.3 million during FY2024, and its lowest value of $22.7 million during FY2020.
  • Its 3-year average for Interest Expenses is $58.3 million, with a median of $59.0 million in 2023.
  • Data for Esperion Therapeutics' Interest Expenses shows a peak YoY surged of 179.19% (in 2020) over the last 5 years.
  • Esperion Therapeutics' Interest Expenses (Yearly) stood at $22.7 million in 2020, then soared by 104.47% to $46.4 million in 2021, then climbed by 22.56% to $56.8 million in 2022, then increased by 3.81% to $59.0 million in 2023, then grew by 0.47% to $59.3 million in 2024.